Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database
ObjectiveTo explore the durability of multi-drug antiretroviral regimens in treatment-experienced PWH.DesignThis retrospective observational study including PWH who started mega-ART regimens between 1 January 2009 and 31 December 2019, selected from the ARCA cohort.MethodsTime-dependent events were analysed by Kaplan-Meier methods, while Cox regression models were used to define the predictors of mega-ART discontinuation.ResultsA total of 1,514 ART-experienced PWH were included. Over a median follow-up of 47 weeks (IQR 15-127), 1,299 (83%) mega-ART were interrupted, with an incidence of 85.62 per 100 person-years of follow-up. In the multivariable analysis, predictors of higher risk of mega-ART discontinuation were a higher number of antiretroviral drugs included in baseline regimens (aHR 1.206, CI 95% 1.016-1.431, <i>p</i> = .032) and a higher baseline HIV RNA log<sub>10</sub> (aHR 1.113, CI 95% 1.048-1.181, <i>p</i> < .001); otherwise, shorter duration of previous ART was associated with a lower risk of discontinuation (aHR 0.982, CI 95% 0.965-0.999, <i>p</i> = .037). When mega-ART was stopped, 299 PWH (23%) had HIV RNA levels above 50 copies/ml, 16/299 (1%) had HIV RNA levels >50 copies/ml but less than 200 copies/ml, 792 PWH (61%) had HIV RNA levels below 50 copies/ml, and 208 PWH (16%) had an undetermined HIV RNA load.ConclusionsMega-ART was characterized by limited durability and poor virological success.
Authors
- Costanza Malcontenti
- Maurizio Zazzi (ORCID: https://orcid.org/0000-0002-0344-6281)
- Antonio Di Biagio (ORCID: https://orcid.org/0000-0003-1436-5089)
- Laura Labate
- Fiorenza Bracchitta
- Martina Bottanelli (ORCID: https://orcid.org/0000-0003-1162-3513)
- Adrian Shallvari
- Sara Mora (ORCID: https://orcid.org/0000-0002-0613-3248)
- Antonia Bezenchek
- Marta Tilli (ORCID: https://orcid.org/0000-0002-2097-2443)
- Chiara Cassol (ORCID: https://orcid.org/0000-0001-8976-1671)
- Lucia Graziani (ORCID: https://orcid.org/0000-0003-4829-9796)
- Barbara Rossetti
- Rebecka Papaioannu Borjesson (ORCID: https://orcid.org/0009-0007-6486-2231)
- Chiara Russo (ORCID: https://orcid.org/0000-0002-0917-1936)
- Laura Rancan
Institutions
- University of Siena (IT)
- Vita-Salute San Raffaele University (IT)
- Genesis HealthCare (US)
- Martin University (US)
- San Raffaele University of Rome (IT)
- Luigi Sacco Hospital (IT)
- Centro Nacional de Información Geográfica (ES)
- Informa (Italy) (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Ospedale Misericordia - Grosseto (IT)
- European Society of Concurrent Enterprising Network (IT)
- Ospedale Policlinico San Martino (IT)
- ASST Fatebenefratelli Sacco (IT)
- University of Florence (IT)
- University of Genoa (IT)
Publication Details
- Journal
- Antiviral Therapy
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1177/13596535251317054
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40